MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/10428194.2026.2707442

Медицинская библиотека · Leukemia & lymphoma · 2026

Efficacy of imatinib maintenance after stem cell transplantation for Ph+/BCR::ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.

Pfeifer Heike, Bethge Wolfgang, Schönland Stefan, Heberling Lisa, Ruhnke Leo, Stadler Michael, Beelen Dietrich, Vučinić Vladan, Burmeister Thomas, Stelljes Matthias, Faul Christoph, Kiani Alexander, Wendelin Knut, Schwerdtfeger Rainer, Lange Elisabeth, Kubuschok Boris, Horst Heinz-August, Gramatzki Martin, Serve Hubert, Hoelzer Dieter, Gökbuget Nicola, Ottmann Oliver G, Lang Fabian, GMALL Study Group

СтатьяПеревод в очереди

Аннотация

Tyrosine kinase inhibitors are recommended as maintenance therapy following allogeneic stem cell transplantation (HSCT) for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), but optimal medication, dose, and duration remain a subject of ongoing study. We provide the final analysis of a prospective randomized trial comparing prophylactic and minimal residual disease (MRD)-triggered imatinib maintenance. The two patient cohorts did not differ significantly in terms of cumulative incidence of relapse (CIR; 14% vs. 18%), non-relapse mortality (NRM; 12% vs. 11%), leukemia-free survival (LFS) 64% vs. 69%, and overall survival (OS) at 10 years (68% vs. 71%). Endpoints were assessed every 6 weeks within the trial from 4 weeks after SCT until EOS at week 55 and after that according to local standards. In summary, this provides a framework for MRD-based treatment of patients for maintenance after HSCT with excellent long-term outcome after 10 years in both groups.

Для цитирования: Pfeifer Heike, Bethge Wolfgang, Schönland Stefan, Heberling Lisa, Ruhnke Leo, Stadler Michael, Beelen Dietrich, Vučinić Vladan, Burmeister Thomas, Stelljes Matthias, Faul Christoph, Kiani Alexander, Wendelin Knut, Schwerdtfeger Rainer, Lange Elisabeth, Kubuschok Boris, Horst Heinz-August, Gramatzki Martin, Serve Hubert, Hoelzer Dieter, Gökbuget Nicola, Ottmann Oliver G, Lang Fabian, GMALL Study Group. Efficacy of imatinib maintenance after stem cell transplantation for Ph+/BCR::ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.. Leukemia & lymphoma. 2026. DOI: 10.1080/10428194.2026.2707442.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.